In response to DNA damage, TLS (translesion synthesis) allows replicative bypass of various DNA lesions, which stall normal replication. TLS is achieved by low-fidelity polymerases harbouring less stringent active sites. In humans, Y-family polymerases together with Polζ (polymerase ζ ) are responsible for TLS across different types of damage. Protein-protein interaction contributes significantly to the regulation of TLS. REV1 plays a central role in TLS because it interacts with all other Y-family members and Polζ . Ubiquitin-dependent regulatory mechanisms also play important roles in TLS. Ubiquitin-binding domains have been found in TLS polymerases and they might be required for TLS activity. Mono-ubiquitination of PCNA (proliferating-cell nuclear antigen), the central scaffold of TLS polymerases, is thought to promote TLS. In addition, both nonproteolytic and proteolytic polyubiquitination of PCNA and TLS polymerases has been demonstrated. Owing to their low fidelity, the recruitment of TLS polymerases is strictly restricted to stalled replication forks.
Introduction
Transmission of genetic materials from one generation to the next is the essence of life. Organisms have evolved accurate machineries to ensure faithful replication of the DNA genome. Replicative DNA polymerases are characteristic for their high processivity and high fidelity which are achieved by their stringent active sites and the 3 →5 proofreading exonuclease activity. DNA, however, is constantly subject to damage caused by both extrinsic and intrinsic agents, such as UV light and reactive oxygen species. In order to maintain the integrity of the genome, cells are endowed with elaborate DNA damage repair mechanisms, including nucleotide excision repair, base excision repair, mismatch repair, homologous recombination and non-homologous end joining, to remove DNA lesions before replication starts. However, some damage may evade the repair machinery and persist in the genome. Such lesions on DNA template hinder the incorporation of nucleotides by replicative DNA polymerases because the stringent active sites of these polymerases accommodate normal template bases and correct complementary nucleotides only. Consequently, unrepaired DNA lesions cause replication block. Since stalled replication forks can lead to major chromosome abnormalities and cell death, replicative arrests have to be circumvented to maintain cell survival. Cells have evolved DNA damage tolerance or post-replicative repair mechanisms to bypass damage, restoring DNA replication. One proposed lesion-bypass pathway involves template switching in which the undamaged sister chromatid, instead of the damaged strand, is used as a template for DNA replication in order to restore the correct sequence opposite the lesion. This pathway is generally considered to be error-free and the proposed models are discussed in a recent review [1] .
Another DNA damage tolerance pathway which is extensively studied is TLS (translesion synthesis), in which nucleotides are inserted opposite the lesion, without repairing it. TLS employs specialized DNA polymerases which lack proofreading activity and have low processivity as well as low fidelity. In contrast with replicative polymerases, their active sites are more relaxed and thus can accommodate bulky distorted damaged bases [2] . TLS is evolutionarily conserved, and the proteins involved can be found in bacteria and in both lower and higher eukaryotes. Most of these proteins belong to the Y-family of DNA polymerases, a new family following five preceding ones (A, B, C, D and X). In bacteria, there are DNA Pol (polymerase) IV and Pol V. In budding yeast, there are two members, REV1 and Polη. In mammals, Y-family polymerases expand to four members, REV1, Polη, Polι and Polκ, implying the complexity of TLS in higher eukaryotes [3] . In addition to Y-family polymerases in eukaryotes, Polζ is a member of the B-family DNA polymerases, which include high-fidelity replicative polymerases such as Pols α, δ and ε, yet displays TLS activity. Polζ is capable of extending terminally mismatched or distorted primers opposite to DNA lesions more efficiently than Polα. Like Y-family polymerases, Polζ has low processivity [4] and does not possess 3 →5 proofreading exonuclease activity [5] . thumb, fingers and palm domains, in the central region of the proteins. Structural studies of TLS DNA polymerases, however, reveal that the thumb and finger domains are remarkably shorter than those in replicative DNA polymerases. This structure gives a more open and relaxed active site to accommodate bulky DNA lesions and to allow mismatched base pairing to occur. Such loose conformation generates a considerably smaller interface between DNA and the catalytic core. Consequently, the 'induced-fit' conformational change around the active site is apparently destroyed, conferring low fidelity on Y-family polymerases [6] . In addition to the catalytic core, Y-family DNA polymerases also harbour a little finger domain, also referred to as PAD (polymerase-associated domain), at the C-terminus of the catalytic core. PAD extends from the fingers domain to mediate DNA binding and the movement of primer-template duplex [2] . The interaction between PAD and the primer-template duplex after nucleotide insertion opposite the damaged base is proposed to trigger polymerase switch, probably through conformational change [7] . Although the amino acid sequence of PAD is relatively diverse among the members of Y-family polymerases, its structural conformation is conserved. Noticeably, the diversity of PAD sequence may contribute to the differences in lesion specificity among the members in the family [2] .
In general, TLS is considered to be a mutagenic process owing to the low fidelity of polymerases involved. However, some TLS polymerases are capable of replicating over certain lesions efficiently and with considerable accuracy; one prominent error-free example of TLS is carried out by Polη. Polη is found exclusively in eukaryotes and it is particularly important to humans because of its protective role against skin cancer. Loss of Polη activity is identified in a genetic disorder known as XPV (xeroderma pigmentosum variant), which is more vulnerable to skin cancer and has higher sensitivity to sunlight [8] . Polη is able to accurately and efficiently replicate through CPDs (cyclobutane pyrimidine dimers), a major UV-induced DNA lesion [9] . Elevated UV-induced mutation frequency is observed in Polη-knockout mouse embryonic fibroblasts [10] . On the other hand, overexpression of Polη does not increase spontaneous mutation in human cells [11] . It is apparent that Polη is specialized for the bypass of CPDs in an error-free manner, and this accurate process is less likely to be replaced by other polymerases in the family. In support of this, human Polη has low processivity with undamaged DNA, whereas the processivity increases remarkably when it bypasses cis-syn thymine dimers, and it preferentially inserts dATP opposite both thymines [7] . In primary fibroblasts of Polη-knockout mice, UV-induced mutagenesis is largely suppressed by depletion of Polι [12] . This implies that individual mammalian TLS polymerase may target specific lesions induced by various DNA-damaging agents.
In spite of the conservation of polymerase catalytic core, REV1 is a dCMP transferase with restricted activity in inserting dCMP not only opposite template G, but also opposite other template bases [13] . At the N-terminus of REV1, there is a BRCT [BRCA1 (breast cancer earlyonset 1) C-terminal] domain, which is unique among Y-family members. The BRCT domain is required for REV1 to bind PCNA (proliferating-cell nuclear antigen). Deletion or inactivation of the BRCT domain abrogates the localization of REV1 to replication foci in the nucleus. The BRCT domain is also required for cell survival and DNAdamage-induced mutagenesis in yeast and chicken DT40 cells [3] . Notably, BRCT domain and dCMP transferase activity of human REV1 are not required for effective DNA damage tolerance [14] . It is therefore obvious that the BRCT domain provides another layer of regulation for REV1, which is absent from other members of Y-family polymerases.
REV1 plays a pivotal role in maintaining genomic integrity by TLS and works closely with Polζ for most spontaneous and induced mutagenesis in yeast [3] . REV1 physically binds to many proteins in the TLS pathway. The C-terminal 100-150 amino acids of mammalian REV1 can interact with other Y-family polymerases, including Pols η, κ and ι ( Figure 1 ), whereas PAD of REV1 binds Polη in yeast [15] . The sequence homology in the C-terminal region of REV1 is more conserved among higher vertebrates (such as humans and mice) than among lower eukaryotes (for example, fungi and yeast) [16] . This may explain the variation of binding targets between human and yeast REV1 orthologues. Very recently, a novel RIR (REV1-interacting region) has been identified in the C-terminal region of human Pols κ, ι, and η [17] . Polκ mutant deficient in RIR is unable to restore UV resistance of Polκ-null cells [17] . BRCT domain, PAD as well as the C-terminal region of yeast REV1 are capable of physically interacting with REV7, the accessory subunit of Polζ [18] . Besides binding to REV7 [19] , the C-terminus of yeast REV1 can also bind to REV3, the catalytic subunit of Polζ , and this interaction promotes the proficiency of Polζ for mismatch extension and extension opposite DNA lesions [20] . Interaction between REV1 and REV7 is conserved in all organisms, including yeast, mice and humans, indicating the important role of REV1 in TLS by Polζ . It is noteworthy that the dCMP transferase activity of yeast REV1 is not required for UV mutagenesis because dCMP is rarely inserted opposite UVinduced lesions [21] . Furthermore, the transferase activity of REV1 is dispensable for the bypass of abasic sites [22] and lesions modified by N-2-acetylaminofluorene [23] . Both yeast wild-type REV1 and its polymerase-deficient mutant are capable of interacting with REV3 and REV7 independently and these complexes are localized to DNA lesions [24] . Taken together, REV1 probably serves a structural role in TLS by Polζ .
Polζ is a heterodimeric complex comprising REV3 and REV7. Upon binding to REV7, the catalytic activity of REV3 is enhanced [4] . Like REV1, Polζ is a TLS enzyme conserved in eukaryotes, from yeast to humans. Nevertheless, polymerase activity has not been demonstrated in mammalian Polζ , in contrast with its yeast and Drosophila counterparts [4, 25] . Both REV3 and REV7 belong to the B-family of DNA polymerases, and Polζ possesses a relatively higher fidelity than Y-family polymerases, even though REV3 is devoid of 3 →5 proofreading exonuclease activity [4] . Although Mammalian Y-family polymerases consist of REV1, Polκ, Polι and Polη. REV1 interacts with Polκ, Polι and Polη using its C-terminal 100-150 residues. Two UBMs (UBM1 and UBM2) of REV1 are required for the association with PCNA which is mono-ubiquitinated at Lys 164 (K164) during DNA damage. Similarly, ubiquitin-binding domains at the C-termini of other Y-family polymerases (UBZ of Polκ and Polη, and UBM of Polι) are able to interact with mono-ubiquitinated PCNA. PCNA is a homotrimer, and it is plausible that all subunits may be mono-ubiquitinated, thus interacting with three proteins at the same time. All Y-family polymerases, except for REV1, possess PIP which can bind PCNA regardless of the ubiquitination state of PCNA. Although REV1 lacks PIP, the BRCT domain at the N-terminus of REV1 is responsible for interacting with PCNA. REV7, the accessory subunit of Polζ , interacts with the catalytic subunit REV3 and promotes its activity. REV7 binds to the C-terminal region of REV1 without affecting its activity. REV7 can interact with the activator of APC, Cdh1 and/or Cdc20, thereby inhibiting the activation of APC. APC is an E3 ubiquitin ligase which covalently conjugates ubiquitin moiety to target substrates subject to proteasomal degradation. Ub, ubiquitin.
Polζ is not efficient in replicating through DNA lesions, it is competent to extend from mispaired primer termini. Therefore the primary role of Polζ in TLS is proposed to extend from the nucleotides inserted opposite the lesion by other TLS enzyme(s) [3] . One example is that human Polι and Polζ co-operate sequentially in a way that the former inserts nucleotides opposite damage sites and the latter acts as an primer-extension enzyme [26] . We have demonstrated that suppression of human REV7 in cultured cancer cells using the RNAi (RNA interference) technique results in hypersensitivity to DNA-damaging agents, impaired sister chromatid exchange, reduction in frequencies of spontaneous and drug-induced mutations, and an increase in chromosome aberration in response to DNA damage [27] . These findings agree with the observations in avian cells, implicating the evolutionarily conserved role of REV7 in the DNA damage pathway in eukaryotes. Reduction of REV3 expression in yeast substantially decreases UV-induced mutation frequency [5] and disruption of the Rev3 gene in mice is embryonic lethal. Mouse cells with the Rev3 gene interrupted have lower survival rates and more cells arrested in S-or G 2 / M-phase of the cell cycle [28] . Chicken DT40 cells with homologous deletion of REV3 are sensitive to DNAdamaging agents and cells are accumulated in G 2 phase [29] . These data suggest that the functional role of REV3 in TLS is conserved among species. In yeast, REV3-deleted cells arrest in G 2 upon UV irradiation [30] . Intriguingly, yeast REV1 is expressed in a cell-cycle-dependent manner, in which REV1 mRNA and protein levels peak at G 2 /M-phase and this expression profile does not alter drastically after DNA damage by UV [2] . Given the indispensability of REV1 in TLS by Polζ , yeast and mammalian models suggest that REV3 functions after S-phase, conceivably in G 2 /M-phase, and this coincides with the expression pattern of REV1, highlighting the tight functional relationship between these two TLS proteins.
Apart from its role in TLS, REV7 has another identity in cell-cycle regulation. Human REV7 is also called MAD2B, MAD2L2 or MAD2β for its high sequence homology with a mitotic checkpoint protein MAD2 [31, 32] . Like MAD2, MAD2B is able to bind Cdh1 and/or Cdc20, activators of APC (anaphase-promoting complex), thereby inhibiting APC activation. Although MAD2B is homologous with MAD2, it does not bind to MAD1, an anchoring protein for MAD2 at the kinetochore at the onset of mitotic checkpoint, suggesting that MAD2B may deliver signal other than mitotic checkpoint activation to the APC-mediated proteolytic pathway [31, 32] . The role of MAD2B in mitotic checkpoint is also demonstrated in the infection process of intestinal epithelial cells by Shigella. IpaB, an effector protein in Shigella for bacterial invasion of host cells, interacts with MAD2B in G 2 /M-phase, leading to unscheduled activation of APC Cdh1 and subsequent degradation of APC substrates such as cyclin B and Cdc20, which in turn elicits G 2 /M-phase arrest [33] . The novel role of REV7 in mitotic checkpoint, which in particular is associated with APC-mediated proteolysis, hints that REV7 may act as a mediator to link between ubiquitin-mediated proteolysis and DNA damage pathways [34] . Identification of REV7 targets for protein degradation can therefore provide evidence to support the cross-talk between these two important pathways in cells (Figure 1 ).
Role of ubiquitin in TLS
In order to implement TLS, the access and recruitment of TLS proteins to a damaged site are prerequisites. Eukaryotic PCNA is a homotrimeric protein which constitutes a doughnut-shaped structure surrounding double-stranded DNA. It slides along DNA during replication, providing a platform to tether the replicative polymerases to the DNA template. Since the replication fork is stalled at DNA lesions, it is perceived that PCNA also serves as a docking site for TLS proteins. Indeed, all eukaryotic Y-family polymerases, except REV1, contain PIP (PCNA-interacting peptide), which allows them to interact with PCNA, whereas the binding with PCNA requires the BRCT domain of REV1 [3] . REV1 protein localizes to the nucleus exclusively and co-localizes with PCNA in replication foci, the replication machineries in S-phase cells, only when the BRCT domain is intact. Considering that Y-family polymerases can associate with PCNA and mammalian REV1 is able to interact with other members in the Y-family and Polζ (Figure 1) , it is tempting to speculate that TLS polymerases display high avidity towards PCNA, like replicative polymerases. In fact, the recruitment of TLS polymerases is regulated rigidly through post-translational modification of PCNA by ubiquitin. 'Polymerase switch' is a generally accepted model in which PCNA acts as a platform where replicative polymerases are switched to TLS polymerases to carry out lesion bypass [35] . In response to DNA damage, a replication fork is stalled at a lesion where single-stranded DNA is generated and this triggers the activation of an E3 ubiquitin ligase RAD18. RAD18, together with an E2 ubiquitin-conjugating enzyme RAD6, forms an E2-E3 complex which mono-ubiquitinates PCNA at Lys 164 . Meanwhile, USP1 (ubiquitin-specific protease 1), a deubiquitinase, is degraded by an autocleavage mechanism to prevent the removal of ubiquitin from PCNA [36] . The activation of ubiquitin ligase and inactivation of deubiquitinase deliberately promote the formation of mono-ubiquitinated PCNA persistently, which consequently promotes TLS [37] . Although PCNA is thought to be mono-ubiquitinated only when it is loaded at a stalled replication fork, PCNA mono-ubiquitination is dispensable for fork progression on damaged DNA, but is required for post-replicative gap filling [38] . Noticeably, mono-ubiquitinated PCNA particularly activates Polη and REV1, concurring with a role in promoting TLS [35] . In addition, PCNA is mono-ubiquitinated in a RAD18-dependent manner upon UV irradiation of human cells, and Polη only interacts with mono-ubiquitinated PCNA, but not unmodified PCNA [39] . PCNA monoubiquitination is also required for Polη-dependent error-free incorporation of dCMP opposite 8-oxoguanine [40] .
UBM (ubiquitin-binding motif) and UBZ (ubiquitinbinding zinc finger) domains have been found in TLS polymerases [41] . These domains are evolutionarily conserved in all Y-family polymerases and are located at the C-terminal region of the proteins [3] . With possible exceptions [42] , UBM and UBZ are generally required for polymerases to bind ubiquitin and to localize to replication foci [43, 44] . In particular, they promote robust interaction between TLS polymerases and mono-ubiquitinated PCNA [45, 46] . In the absence of DNA damage, mono-ubiquitination of PCNA is inhibited by deubiquitinase USP1, thereby prohibiting the switch from replicative to TLS polymerases. The timely mono-ubiquitination of PCNA during DNA damage therefore confers a spatial and temporal regulation on recruitment of TLS proteins to bypass lesions. Structural analysis reveals that PIP of Polη interacts with PCNA more strongly than does UBM [47] . The relative affinity between different PCNA-binding motifs hence could limit the binding of Polη to mono-ubiquitinated PCNA, rather than other ubiquitinated products induced by DNA damage. Since all three monomers of PCNA can be mono-ubiquitinated simultaneously and mono-ubiquitinated PCNA does not alter the activity of replicative DNA polymerase, it is possible that replicative DNA polymerases may not be displaced from PCNA during TLS at lesion sites [42] . On the other hand, each mono-ubiquitinated monomer may bind to a different TLS polymerase which attempts to access the stalled primer terminus on a trial and error basis [3] . However, the exact mechanism of polymerase switching remains to be elucidated.
The massive interactions among the members of TLS polymerases, and between these members and PCNA via ubiquitin, together with distinct efficacies of TLS polymerases towards various lesions, impose the idea of a two-step model in which two polymerases are involved in TLS. For example, Polη binds to and targets Polι to replication foci [48] . Polζ is not efficient in inserting nucleotides opposite DNA lesions while it efficiently extends from nucleotides. It thus cooperates with other polymerases for incorporating nucleotides to achieve TLS [22, 26, 49] , and various combinations of the two polymerases also determine the activation of either error-free or error-prone pathways [49] .
It is not surprising that PCNA and TLS polymerases can also be regulated by polyubiquitination. Modification of PCNA at Lys 164 with Lys 63 -linked polyubiquitin chain by yeast RAD5 and mammalian HLTF (helicase-like transcription factor)/SHPRH (SNF2 histone linker PHD ring helicase) does not cause proteolysis, but prevents TLS by promoting error-free damage avoidance [50] [51] [52] . On the other hand, polyubiquitination-dependent proteasomal degradation of yeast Polη has been demonstrated [53] . This raises the interesting question as to whether the stability of other TLS polymerases might also be regulated by polyubiquitination and degradation. In particular, because REV7 interacts with REV1 and REV3 [19] on one hand and regulates APC Cdh1 or APC Cdc20 on the other, it will be of great interest to investigate whether REV1 and REV3 might undergo APC-dependent proteolysis through their interaction with REV7 ( Figure 1) . Plausibly, polyubiquitination of PCNA and TLS polymerases both associated and not associated with proteasome-dependent protein degradation might serve important regulatory roles in TLS.
Conclusion
TLS is an important DNA damage tolerance pathway and it employs low-fidelity polymerases to replicate across lesions, which arrest replication by replicative polymerases. Identification of different binding domains, such as RIR for REV1 binding, and PIP plus UBM for PCNA binding, in TLS polymerases enables us to comprehend the functional relationship among these proteins. TLS polymerases have low fidelity, introducing mutations in the genome. Therefore strict control of TLS polymerases is essential. Ubiquitin-dependent regulation of TLS polymerases is known to execute at different levels. Mono-ubiquitination of scaffold protein PCNA and its subsequent interaction with TLS polymerases are a key regulatory step that recruits TLS polymerases to the lesions. However, further investigations are required to elucidate the detailed mechanism of polymerase switching. Yeast REV1 protein is expressed in a cell-cycle-dependent manner in which the level peaks at G 2 /M-phase. Yeast Polη has fast protein turnover, which is regulated by proteasome-mediated degradation. It remains elusive whether expression levels of other TLS polymerases in yeast and humans are regulated in response to DNA damage. Post-translational modification of proteins, such as ubiquitination and phosphorylation, can modulate protein stability, localization, activity and protein interaction, and direct the target proteins to different signalling pathways. Hence a comprehensive repertoire of TLS protein modifications would lend us insights into the regulation of and the interrelation of the components in TLS. Polζ is a key protein in TLS, and its subunit REV7 also participates in mitotic checkpoint in which it inhibits the APC-proteasome pathway. If TLS polymerases are able to be covalently linked to ubiquitin, they can be our targets of study to investigate whether there is cross-talk between DNA damage tolerance and ubiquitination machinery.
